XHKG1652
Market cap75mUSD
Dec 23, Last price
0.81HKD
1D
0.00%
1Q
-19.00%
IPO
-65.82%
Name
Fusen Pharmaceutical Co Ltd
Chart & Performance
P/E
—
P/S
0.98
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.60%
Rev. gr., 5y
4.13%
Revenues
566m
+15.02%
Net income
-36m
L+4.68%
CFO
-73m
L
Dividend
Jun 07, 20220.0042 HKD/sh
Earnings
May 28, 2025
Profile
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 565,608 15.02% | 491,757 27.51% | 385,664 -20.78% | ||||||
Cost of revenue | 561,523 | 470,754 | 341,352 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 4,085 | 21,003 | 44,312 | ||||||
NOPBT Margin | 0.72% | 4.27% | 11.49% | ||||||
Operating Taxes | 6,847 | 3,661 | 7,178 | ||||||
Tax Rate | 167.61% | 17.43% | 16.20% | ||||||
NOPAT | (2,762) | 17,342 | 37,134 | ||||||
Net income | (36,277) 4.68% | (34,654) -308.19% | 16,645 -76.27% | ||||||
Dividends | (6,959) | (8,306) | |||||||
Dividend yield | 0.64% | 0.87% | |||||||
Proceeds from repurchase of equity | (15,988) | (10,073) | (7,390) | ||||||
BB yield | 1.55% | 0.93% | 0.77% | ||||||
| Debt | |||||||||
Debt current | 237,643 | 227,949 | 162,748 | ||||||
Long-term debt | 108,331 | 2,971 | 81,713 | ||||||
Deferred revenue | 10,231 | 11,323 | 10,508 | ||||||
Other long-term liabilities | |||||||||
Net debt | 162,151 | (70,900) | (34,666) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (73,334) | 110,490 | 47,766 | ||||||
CAPEX | (66,241) | (23,862) | (110,133) | ||||||
Cash from investing activities | (108,318) | (13,131) | (282,977) | ||||||
Cash from financing activities | 88,503 | (51,766) | 20,527 | ||||||
FCF | (377,992) | 82,303 | (104,195) | ||||||
| Balance | |||||||||
Cash | 34,849 | 128,106 | 81,705 | ||||||
Long term investments | 148,974 | 173,714 | 197,422 | ||||||
Excess cash | 155,543 | 277,232 | 259,844 | ||||||
Stockholders' equity | 331,533 | 312,141 | 343,458 | ||||||
Invested Capital | 761,029 | 543,537 | 619,462 | ||||||
ROIC | 2.98% | 6.70% | |||||||
ROCE | 0.45% | 2.55% | 5.01% | ||||||
| EV | |||||||||
Common stock shares outstanding | 752,056 | 756,074 | 770,313 | ||||||
Price | 1.37 -4.20% | 1.43 15.32% | 1.24 -71.82% | ||||||
Market cap | 1,030,317 -4.70% | 1,081,186 13.19% | 955,188 -72.53% | ||||||
EV | 1,191,176 | 1,009,012 | 919,297 | ||||||
EBITDA | 39,883 | 55,164 | 68,097 | ||||||
EV/EBITDA | 29.87 | 18.29 | 13.50 | ||||||
Interest | 12,583 | 12,382 | 8,244 | ||||||
Interest/NOPBT | 308.03% | 58.95% | 18.60% | ||||||